BioAlliance Pharma SA has licensed the China commercialization rights for Loramyc™ to NovaMed Pharmaceuticals. The deal could be worth up to $4.5 million to NovaMed in upfront and milestone payments. NovaMed will seek to win SFDA approval for the product and then market it in China. Loramyc (miconazole Lauriad®) is a muco-adhesive antifungal therapy that is already approved in some European countries for cancer patients with opportunistic infections.  More details... 

Stock Symbol: (Euronext Paris: BIO)